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Objectives. We sought to study the relation between recurrent
ST segment shift within 6 to 24 h of initial resolution of ST
elevation after thrombolytic therapy and 30-day and 1-year mor-
tality.
Background. Rapid and stable resolution of ST segment eleva-
tion in relation to thrombolytic therapy in patients with an acute
myocardial infarction is an indicator of culprit artery patency.
Whether recurrence of ST segment shift during continuous ST
monitoring after initial resolution is related to poor prognosis has
not been studied.
Methods. ST segment monitoring was performed within 30 min
after thrombolytic therapy for acute myocardial infarction. The
predictive value of a new ST segment shift (assessed as >20.1-mV
deviation from the baseline) 6 to 24 h after thrombolytic therapy
was studied with respect to 30-day and 1-year mortality.
Results. Of 734 patients, 243 had a new ST segment shift (33%).
The 30-day mortality rate in patients with an ST shift (7.8%) was
significantly higher than that in patients without an ST shift
(2.25%, p 5 0.001), as was the 1-year mortality rate (10.3% vs.
5.7%, respectively, p 5 0.025). Multivariable analysis revealed an
independent predictive value of ST shift with respect to 30-day
mortality (p 5 0.008), even after consideration of multiple clinical
risk factors in the overall Global Utilization of Streptokinase and
TPA for Occluded Coronary Arteries (GUSTO)-I mortality model
(p 5 0.0001). Moreover, the duration of the ST shift bore a direct
relation with 1-year mortality (p 5 0.008).
Conclusions. Detection of ST segment shift early after throm-
bolytic therapy for acute myocardial infarction is a simple,
noninvasive means of identifying patients at high risk and is
superior to other commonly assessed clinical risk factors. Thus,
patients with a new ST shift after the first 6 h, but within 24 h,
represent a high risk group that may benefit from more aggressive
intervention, whereas patients without evidence of an ST shift
represent a low risk subgroup.
(J Am Coll Cardiol 1998;31:783–9)
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In the setting of acute ischemic syndromes, continuous ST
segment monitoring can be used for the detection of culprit
vessel reperfusion on the basis of rapid and stable resolution of
ST segment elevation (1–9). There is also evidence of a more
frequent unfavorable outcome among patients with an ST
segment shift on continuous monitoring after presentation
with unstable angina(10–15) or after myocardial infarction
(16–22). Although recurrent symptoms and the admission
electrocardiogram (ECG) have predictive value (23,24), sev-
eral studies have found that continuous ST segment monitor-
ing has additional prognostic value (14), independent of such
prognostic indicators as left ventricular dysfunction or angio-
graphic extent of coronary artery disease (15). Thus, ST
segment shift reflects a variety of adverse underlying patho-
physiologic processes in patients with acute ischemic syn-
dromes and has been related not only to angiographic detec-
tion of thrombus (25) but also to cardiac adrenergic
dysfunction (26) and cycles of thrombosis and thrombolysis
(27).
The recently reported Global Utilization of Streptokinase
and TPA [tissue-type plasminogen activator: alteplase] for
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Occluded Coronary Arteries (GUSTO-I) trial (28) and its
angiographic substudy (29) showed improved clinical out-
comes and angiographic patency in patients treated with an
accelerated regimen of alteplase versus streptokinase. The
primary goal of the GUSTO-I ST Segment Monitoring Sub-
study (9) was to provide a noninvasive assessment of the speed
and stability of reperfusion. The prognostic significance of
recurrent ST shift after initial resolution of ST segment
elevation in patients presenting with ST elevation and acute
myocardial infarction has not been studied. Thus, we studied
the relation between recurrent ST shift 6 to 24 h subacutely
after initial resolution of ST elevation after thrombolytic
therapy and 30-day and 1-year mortality.
Methods
Patients. The protocol and results of the GUSTO-I trial
have been published elsewhere (28). Eligible patients were
randomized to receive streptokinase with subcutaneous or
intravenous heparin, accelerated alteplase with intravenous
heparin or the combination of intravenous alteplase and
streptokinase with intravenous heparin.
ST segment monitoring. The details of ST segment moni-
toring have been reported previously (9,30). We aimed to start
ST segment recording within 30 min of thrombolytic treat-
ment, and monitoring continued for 24 h. The GUSTO-I ECG
Monitoring Substudy was a collaborative effort (30) of three
core laboratories, which used one of three ST segment moni-
toring devices: a three-channel (Frank’s orthogonal X, Y, Z
leads) continuous vectorcardiographic monitor (MIDA 1000,
Ortivus Medical, Stockholm, Sweden); a 12-lead continuous
ECG monitor (ST-100, Mortara Instrument); or a three-
channel (bipolar modified V2, V5 and aVF leads) Holter
monitor (Marquette Electronics). ST segment analysis was first
performed in blinded manner as to treatment assignment at
the three core laboratories. ECG editing and interpretation
were performed by an experienced operator with a computer-
assisted device. The technical details of ST segment analysis
for the three monitoring devices have been summarized else-
where (30). The three core laboratories provided edited ST
segment trends as a data stream containing the ST segment
level at 60 ms after the J point, which was used for this analysis.
We evaluated new ST segment shift after resolution of
initial ST elevation within 6 h of thrombolytic therapy (Fig. 1)
on the basis of the following criteria: 1) $50% resolution of
initial ST shift (elevation or depression) in the lead with
maximal ST deviation at the initiation of monitoring (6,9) or if
maximal ST deviation was not detected, for example, because
of the latter hook-up of ST monitoring device, an ST segment
level within 6 h of thrombolysis within 0.2 mV (elevation or
depression) of zero; otherwise, the resolution of initial ST
elevation was not thought to have occurred; 2) duration of
$50% resolution at $10 min within 6 h of thrombolysis; and 3)
new ST segment elevation or depression, defined as $0.1 mV
from the average ST segment baseline .6 h after thrombolysis
and lasting $1 min. The average ST segment baseline value
was calculated from all ST segment data points for the
duration of monitoring beyond the initial 6 h. Thus, ST shift as
discussed here represents a recurrent ST shift .6 h from the
Abbreviations and Acronyms
CI 5 confidence interval
GUSTO 5 Global Utilization of Streptokinase and TPA for Occluded
Coronary Arteries
ECG 5 electrocardiogram, electrocardiographic
OR 5 odds ratio
Figure 1. Average duration of ST shift
per hour for all patients from the time of
thrombolysis. Vertical lines indicate SD.
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time of thrombolytic therapy. Because the duration of moni-
toring varied among patients, the duration of the ST segment
shift for each patient was normalized for 24 h: Normalized
duration of ST segment shift 5 (Actual ST segment shift
duration/Hours of monitoring) 3 24 h. Total ischemic burden
(total ST shift) consisted of ST depression and ST elevation
duration. If both ST segment depression and elevation were
seen in different leads at the same time, the ST shift with
greater ST deviation magnitude was chosen. Excluded from
analysis were patients with ,12 h of effective monitoring time
or a data gap .50% of monitoring time or those in whom
recurrence of ST shift could not be assessed. Many patients
who underwent continuous ST segment monitoring as part of
this substudy also participated in the angiographic substudy
(29). ST segment analysis was not performed during coronary
angiography to exclude ST segment shift in response to
contrast injection or mechanical revascularization.
Statistical analysis. The primary end point was death at 30
days, with a secondary end point of death at 1 year. A
comparison of baseline clinical characteristics of patients in-
cluded in and excluded from this study as well as patients with
and without ST segment shift was performed with chi-square
analysis or an unpaired t test (mean value 6 SD for continuous
variables). The variable of ST duration was normalized with
the logarithmic transformation. The relation between ST seg-
ment shift and death was studied with univariate logistical
regression analysis. The variable “ST segment shift” was then
added to the multivariable model containing the overall 30-day
GUSTO-I mortality model (31). One-year survival analysis
based on the presence of ST shift was performed with Kaplan-
Meier curves. To study the relation between duration of ST
shift and death, 30-min increments of ST shift duration were
chosen on the basis of previous observations (11,12,14,32).
Results
Patient characteristics. Of 1,067 patients who underwent
ST segment monitoring with one of the three devices, 333 were
excluded because of a monitoring time ,12 h, a data gap
duration .50% of monitoring time or other technical difficul-
ties. An additional 41 patients were excluded because resolu-
tion of initial ST shift was not achieved. Patients who were
excluded from the study (n 5 333) were significantly older,
more frequently had an anterior myocardial infarction, re-
ceived thrombolytic therapy later and had a higher mortality
rate at 30 days and 1 year than those included in the study.
Among 734 patients evaluated in this study, 243 (32%) had an
ST segment shift, whereas 491 (67%) patients did not. Among
patients with an ST shift, the median duration of the ST shift
was 30 min, with 25th and 75th percentiles of 7 and 110 min,
respectively; the average duration of the ST shift is shown in
Figure 1.
A comparison of baseline clinical and presenting character-
istics of patients with and without ST segment shift is shown in
Table 1; patients with ST shift were older and more frequently
had diabetes mellitus. There was a trend for a more frequent
history of anterior infarction and cerebrovascular disease, as
well as elevated systolic blood pressure on admission. No
differences were seen in the frequency of administration of
various thrombolytic regimens or in time to treatment (Table
1).
Recurrent ST segment shift and death. The survival disad-
vantage in patients with versus those without an ST segment
shift can be appreciated early and persists for up to one year
(Fig. 2). The mortality rate at 30 days (7.8% vs. 2.25%, odds
ratio [OR] 3.7, 95% confidence interval [CI] 1.7 to 7.9,
p 5 0.008) and at 1 year (10.3% vs. 5.7%, OR 1.9, 95% CI 1.1
to 3.3, p 5 0.025) was higher in patients with than those
without an ST segment shift, respectively. After adjustment
for significant baseline inequalities (Table 1), there contin-
ued to be greater mortality in patients with an ST shift at 30
days (p 5 0.015).
To further define the prognostic significance of ST segment
shift, this variable was added to the overall 30-day GUSTO-I
mortality model (31). When ST shift was added to the overall
mortality model (OR for the model 2.65, 95% CI 1.9 to 3.7) the
duration of the ST shift had an independent and significant
incremental value when considered with 1- or 30-min interval
increases (OR 1.13, 95% CI 1.03 to 1.24, p 5 0.008). To
examine whether a continuous relation existed between the
duration of the ST shift and 1-year mortality rates, we parti-
tioned the ST shift duration into 30-min intervals. As shown in
Figure 3, a good direct relation existed between duration of ST
shift and 1-year mortality (r 5 0.88, p 5 0.008).
Direction of ST segment shift. Among patients with an ST
shift, 92 (38%) had ST depression, and 151 (62%) had ST
elevation. Compared with patients without an ST shift, there
was an increase in the 30-day mortality rate both among those
with ST depression (9.78% vs. 2.25%, p 5 0.0009, OR 4.71,
95% CI 1.89 to 11.72) and those with ST elevation (6.62% vs.
2.25%, p 5 0.012, OR 1.76, 95% CI 1.13 to 2.72). The relation
with higher mortality was maintained after adjustment with the
GUSTO-I mortality model (31) in patients with ST depression
(OR 3.64, 95% CI 1.38 to 9.61, p 5 0.009) or ST elevation (OR
2.43, 95% CI 0.96 to 6.12, p 5 0.06).
Similarly there was an increase in 1-year mortality rates
among patients with ST segment depression compared with
those without an ST shift (11.96% vs. 5.7%, p 5 0.03, OR 2.25,
95% CI 1.08 to 4.69) and ST elevation (9.3% vs. 5.7%, p 5
0.1245, OR 1.30, 95% CI 0.93 to 1.82).
The 30-day prognostic significance of ST depression and
elevation persisted after the elimination of two deaths that
occurred within the first 24 h.
Discussion
The principal novel finding of this study is that a recurrent ST
segment shift detected within 6 to 24 h of thrombolytic
therapy and after the initial resolution of ST elevation is an
independent predictor of 30-day mortality in patients with an
acute myocardial infarction. We also found a direct relation
between the duration of the ST shift and 1-year mortality.
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Previous studies (16–22) have related poor outcome to recur-
rent ischemia detected beyond the first day. Our study extends
those findings of prognostic significance by demonstrating the
importance of early (i.e., within the first 24 h) detection of
ischemia when other noninvasive modalities such as stress
testing are not applicable and within a time frame in which
therapeutic intervention is feasible.
Multiple studies (1–9) have demonstrated that rapid and
stable resolution of ST elevation in patients with an acute
myocardial infarction is related to patency of an infarct-related
artery. Our goal in this respect was to study early risk stratifi-
cation beyond the initial 6 h when patency status has been
established. We were interested in ST segment monitoring
beyond this point to identify high risk patients beyond the time
frame for immediate intervention, such as rescue angioplasty.
ST segment elevation. We observed a higher mortality rate
in patients with recurrent ST segment elevation than in those
without an ST segment shift; however, the pathophysiology
and specificity of ST segment elevation for identifying recur-
rent ischemia could not be determined from our analysis and
remain uncertain. Recurrent ST elevation is thought to reflect
a culprit vessel occlusion (6,33–35). Thus, recurrent ST eleva-
tion in our analysis may have been indicative of recurrent
thrombosis in the infarct-related artery; alternatively, mechan-
ical changes in left ventricular geometry in response to tran-
sient alterations in loading conditions, for example, may ac-
count for the recurrent ST elevation (6–38).
ST segment depression. The pathophysiology of ST seg-
ment depression after myocardial infarction is related to the
severity of culprit lesion stenosis and the dynamic aspects of
the culprit lesion activity, including thrombosis and vasospasm;
these result in more frequent recurrent ischemia, persistent
left ventricular dysfunction, electrical instability and poor
outcome (16,19–22,39). Based on our observations, ST seg-
ment depression appears to have a stronger relation to mor-
tality than does ST segment elevation, especially after adjust-
ment for other variables with the GUSTO-I mortality model
(31). This may suggest that recurrent ST segment depression is
a more specific marker of recurrent ischemia than ST segment
elevation.
Table 1. Clinical Characteristics
No ST Segment Shift
(n 5 491)
ST Segment Shift
(n 5 243) p Value
Age (yr)* 60 6 12 62 6 12 0.005
Male 75.2% 76.5% 0.68
Weight (kg)* 80 6 16 79 6 16 0.38
Height (cm)* 172 6 9 171 6 10 0.45
Smoking history* 68% 71% 0.47
Family history 46% 42% 0.31
Hypercholesterolemia 36% 31% 0.15
Hypertension* 36% 41% 0.26
Systolic blood pressure (mm Hg)* 128 6 20 131 6 24 0.09
Diastolic blood pressure (mm Hg)* 78 6 14 79 6 15 0.21
Heart rate (beats/min)* 74 6 16 74 6 17 0.92
Previous bypass surgery* 4.7% 4.5% 0.92
Previous angina 40% 35% 0.22
Previous myocardial infarction* 12% 15% 0.26
Previous cerebrovascular accident* 0.6% 2.1% 0.08










Time to treatment (h)* 3.0 6 1.5 3.0 6 1.6 0.91
Treatment* 0.55
Accelerated t-PA 25% 23%
Streptokinase1IV heparin 21% 26%
Streptokinase1SQ heparin 26% 24%
t-PA1streptokinase 28% 28%
Peak creatine kinase-MB (IU/liter) 162 6 162 191 6 165 0.10
*Included in GUSTO-I mortality model (31). Data presented are mean value 6 SD or percent of patients. IV 5
intravenous; SQ 5 subcutaneous; t-PA 5 tissue-type plasminogen activator.
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Total ischemic burden. We demonstrated the prognostic
significance of ST segment depression and ST segment eleva-
tion with respect to 30-day or 1-year mortality, suggesting that
the measure of overall ST segment shift can be used for
prognostic risk stratification, at least when acquired within the
first 24 h after acute myocardial infarction. Further insight into
the mechanism of our findings would have been provided by
concurrent measures of infarct size and ventricular function as
well as the status of the culprit vessel.
With acute ischemic syndromes, ST segment shift may be a
marker of myocardial ischemia or necrosis depending on the
underlying pathophysiology, which can include intracoronary
thrombosis, vasoconstriction, distal embolization and micro-
vascular injury. Dynamic changes in ST segments on continu-
ous monitoring have been related to angiographic detection of
intracoronary thrombosis (25), cardiac adrenergic dysfunction
(26) and thrombus-mediated cycles in coronary flow (27).
Thus, ST segment shift represents a convenient surrogate
measure of underlying pathophysiology because it is readily
available, can be continuously updated, quantitatively relates
to the extent of myocardial cell injury in real time and bears a
relation to prognosis. The relation of ST segment monitoring
to other markers of higher risk patients (40,41) requires
further evaluation.
In this era of fiscal restraint and diminishing access to more
intense therapy, our findings provide support for the use of this
Figure 2. Kaplan-Meier survival curves
for patients with ST shift (dashed line)
and those without ST shift (solid line)
demonstrating a significant difference in
1-year mortality rates. Overall number
of patients available for follow-up at
each point in time is also shown.
Figure 3. Relation between dura-
tion of ST shift within the first 24 h
after myocardial infarction and
1-year mortality rates (r 5 0.88).
Duration of ST shift was grouped
on the basis of 30-min intervals and
plotted against the respective mor-
tality (average) rate for each group
of patients. Significance level is
based on univariate analysis of ST
shift.
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noninvasive and universally available marker of recurrent
ischemia for risk stratification. Studies have shown a lack of
benefit from the indiscriminate use of target lesion angioplasty
in patients early after myocardial infarction (42–51). Our study
provides support for the triage of patients with ST shift who
represent a high risk group; this increased risk may be medi-
ated by reocclusion of the infarct-related artery or recurrent
ischemia. This approach is further supported by the findings of
a continuous relation between the duration of ST segment shift
and death (Fig. 3) and by the independent predictive nature of
ST shift in multivariable analysis, which included the
GUSTO-I 30-day mortality model (31).
Study limitations. The main limitation of our study relates
to the arbitrary selection of a 6-h cutoff period for the
detection of recurrent ST shift after thrombolysis. This choice
was supported by three considerations: 1) Resolution of the
initial ST shift was rapid (Fig. 1), with an apparent “shoulder”
at 6 h. 2) Insight from concurrent participation in the angio-
graphic substudy (35) indicated that by 3 h, up to 80% of
patients experienced $50% resolution of initial maximal ST
shift; only a few patients underwent angiography beyond 3 h in
the first day (29), precluding further assessment of patency in
relation to recurrent ST shift. 3) We wished to study the
prognostic significance of ST shift beyond the initial period of
thrombolysis and related instability. Approximately one third
of patients initially enrolled into this substudy were excluded
for technical reasons, which limits the generalizability of our
findings. The observation of higher mortality rates in the
excluded patients than in the included patients may have
resulted in the dilution of the relation between the new ST shift
and death. It should also be noted that the relation of ST shift
to death was independent of clinical variables and risk factors
documented at the time of randomization. However, we did
not study ST shift in relation to symptomatic recurrence of
ischemia or heart failure or in relation to a particular QRS
configuration (e.g., the development of Q waves). Although
the accuracy of ST shift detection may have been limited by the
use of three different techniques, the concurrence of our
findings within each of the technologies facilitates the gener-
alizability of the results.
Conclusions. Recurrent ST shift at 6 to 24 h after throm-
bolytic therapy for acute myocardial infarction is related to
increased mortality at 30 days and 1 year. This simple, nonin-
vasive monitoring technique may be of additional prognostic
value in the early period after acute myocardial infarction,
when rapid decision making pertaining to the management of
these patients is required. Patients with a recurrent ST shift within
the first 24 h represent a high risk group that may benefit from
more aggressive intervention. Patients without a recurrent ST
shift represent a low risk subgroup that, in the absence of other
high risk features, may be suitable for early discharge.
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